ALK(002940)2023-04-28 16:00Operating Costs and Expenses - Operating costs increased by 74.38% to 230.415 million yuan, mainly due to increased raw material costs[3] - Operating costs increased to 385,934,494.86 yuan, a 31.8% rise from the previous year (292,776,746.73 yuan)[16] - R&D expenses rose by 40.94% to 20.760 million yuan, reflecting increased investment in research and development[3] - R&D expenses grew by 40.9% to 20,760,455.04 yuan compared to 14,730,302.82 yuan in the same period last year[16] Government Subsidies and Other Income - Other income surged by 1028.90% to 19.030 million yuan, primarily due to increased government subsidies[3] - Deferred income rose by 95.46% to 19.025 million yuan, driven by increased government subsidies and the consolidation of Core Biotech[10] Cash Flow and Financing Activities - Investment activities cash flow improved by 79.20%, with net cash outflow decreasing to 41.865 million yuan[7] - Financing activities cash flow turned negative, with a net outflow of 108.128 million yuan, mainly due to loan repayments[7] - Net cash flow from operating activities was 84,860,705.56 yuan, a 5.6% decrease compared to 89,918,248.97 yuan in the same period last year[18] - Cash received from sales of goods and services decreased to RMB 425.59 million from RMB 452.23 million[23] - Cash paid for goods and services increased to RMB 156.36 million from RMB 138.22 million[23] Revenue and Profit - Revenue for the first quarter increased by 25.52% to 424,507,176.32 yuan compared to the same period last year[13] - Revenue for the first quarter of 2023 reached 424,507,176.32 yuan, a 25.5% increase compared to the same period last year (338,209,274.21 yuan)[16] - Net profit attributable to shareholders of the listed company rose by 20.43% to 47,070,207.68 yuan year-on-year[13] - Net profit attributable to the parent company's owners was 47,070,207.68 yuan, up 20.4% year-over-year (39,086,498.56 yuan)[17] - Basic earnings per share (EPS) for the quarter was 0.34 yuan, up from 0.29 yuan in the previous year[17] Assets and Liabilities - Total assets grew by 11.75% to 2,901,032,233.82 yuan compared to the end of the previous year[13] - Total assets increased to 2,843,567,890.12 yuan, up from 2,789,456,789.23 yuan at the beginning of the year[19] - Accounts receivable increased by 63.66% to 32,901,271.84 yuan due to higher bank acceptance bills[14] - Inventory surged by 45.84% to 427,654,334.58 yuan mainly due to the inclusion of Core Biotech in the consolidation[14] - Goodwill skyrocketed by 1374.31% to 323,998,277.56 yuan as a result of recognizing goodwill from Core Biotech's inclusion[14] - Short-term borrowings decreased by 44.74% to 94,046,255.00 yuan due to partial repayment of bank loans[14] - Short-term borrowings decreased to RMB 94.05 million from RMB 170.18 million[21] - Accounts payable jumped by 129.67% to 223,484,300.63 yuan owing to increased raw material payments[14] - Accounts payable increased to RMB 223.48 million from RMB 97.31 million[21] - Contract liabilities decreased by 54.74% to 14.965 million yuan, reflecting reduced prepayments from customers[10] - Contract liabilities decreased to RMB 14.97 million from RMB 33.07 million[21] - Other payables increased by 88.78% to 310.046 million yuan, mainly due to the acquisition of Core Biotech[10] - Deferred tax liabilities surged by 936.49% to 16.631 million yuan, due to the revaluation of Core Biotech[10] - Total current liabilities increased to RMB 859.19 million from RMB 788.59 million[21] - Long-term borrowings increased to RMB 192.05 million from RMB 150.00 million[21] - Total liabilities increased to RMB 1.09 billion from RMB 949.93 million[21] - Total equity increased to RMB 1.81 billion from RMB 1.65 billion[21] Shareholder Information - The company's first employee stock ownership plan holds 2.15% of shares, totaling 2,987,000 shares[15] - The top 10 shareholders hold a significant portion of the company's shares, with the largest being Shengzhou Juntao Investment Co., Ltd. at 49,300,000 shares[15] - The company's largest shareholder, Shengzhou Juntao Investment Co., Ltd., holds a 35.44% stake with 49,300,000 shares[20] - The number of ordinary shareholders at the end of the reporting period was 8,962[20] Other Financial Information - The company acquired two land use rights for a total of 25.84 million yuan, expanding its operational footprint[11] - Cash and cash equivalents at the end of the period stood at 663,576,967.12 yuan, a decrease from 728,897,502.12 yuan at the beginning of the period[18] - The company's Q1 report was not audited[24]